The Approach to a Patient with Suspected Laryngopharyngeal Reflux Disease (LPRD)

  • Lawrence Borges
  • Thomas L. CarrollEmail author


Laryngopharyngeal reflux disease (LPR) refers to the symptomatic manifestation of tissue injury that is caused when gastric contents are refluxed retrograde above the level of the upper esophageal sphincter. LPR symptoms can be variable and may include throat symptoms, voice changes, and even disordered swallowing. In addition, LPR symptoms often overlap with other conditions such as other laryngeal pathologies, allergies, and pulmonary disease. This can pose both a diagnostic and therapeutic challenge. In this chapter, we discuss the many ways that LPR may manifest clinically, as well as the common clinical mimickers that should be considered when evaluating a patient with LPR-like symptoms. We then present an overview of the different strategies that are currently available to diagnose LPR – from symptom questionnaires to sophisticated measurement of gastric refluxate – and the relative merits of each. The goal of this chapter is to equip the reader with the knowledge necessary to confidently evaluate the patient with suspected LPR and choose a diagnostic modality that is appropriate for each situation.


Laryngopharyngeal reflux (LPR) Reflux Esophagus Throat Voice Swallow Acid Pepsin pH Impedance Manometry 


  1. 1.
    Cukier-Blaj S, Bewley A, Aviv JE, Murry T. Paradoxical vocal fold motion: a sensory-motor laryngeal disorder. Laryngoscope. 2008;118(2):367–70. Scholar
  2. 2.
    Altman KW, Simpson CB, Amin MR, Abaza M, Balkissoon R, Casiano RR. Cough and paradoxical vocal fold motion. Otolaryngol Head Neck Surg. 2002;127(6):501–11. Scholar
  3. 3.
    Aviv JE, Liu H, Parides M, Kaplan ST, Close LG. Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia. Ann Otol Rhinol Laryngol. 2000;109(11):1000–6. Scholar
  4. 4.
    Devaney KO, Rinaldo A, Ferlito A. Vocal process granuloma of the larynx-recognition, differential diagnosis and treatment. Oral Oncol. 2005;41(7):666–9. Scholar
  5. 5.
    Kang CH, Hentz JG, Lott DG. Muscle tension dysphagia: symptomology and theoretical framework. Otolaryngol Head Neck Surg. 2016;155(5):837–42. Scholar
  6. 6.
    Passaretti S, Mazzoleni G, Vailati C, Testoni PA. Oropharyngeal acid reflux and motility abnormalities of the proximal esophagus. World J Gastroenterol. 2016;22(40):8991. Scholar
  7. 7.
    Fouad YM, Katz PO, Hatlebakk JG, Castell DO. Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. Am J Gastroenterol. 1999;94(6):1464–7. Scholar
  8. 8.
    Patti MG, Debas HT, Pellegrini CA. Clinical and functional characterization of high gastroesophageal reflux. Am J Surg. 1993;165(1):163–6-8. Accessed 9 Oct 2017.CrossRefGoogle Scholar
  9. 9.
    Martinucci I, de Bortoli N, Giacchino M, et al. Esophageal motility abnormalities in gastroesophageal reflux disease. World J Gastrointest Pharmacol Ther. 2014;5(2):86–96. Scholar
  10. 10.
    Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101(4 Pt 2 Suppl 53):1–78. Accessed 19 Sept 2017.CrossRefGoogle Scholar
  11. 11.
    Johnston N, Dettmar PW, Bishwokarma B, Lively MO, Koufman JA. Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoscope. 2007;117(6):1036–9. Scholar
  12. 12.
    Johnston N, Knight J, Dettmar PW, Lively MO, Koufman J. Pepsin and carbonic anhydrase isoenzyme III as diagnostic markers for laryngopharyngeal reflux disease. Laryngoscope. 2004;114(12):2129–34. Scholar
  13. 13.
    Roth DF, Ferguson BJ. Vocal allergy: recent advances in understanding the role of allergy in dysphonia. Curr Opin Otolaryngol Head Neck Surg. 2010;18(3):176–81. Scholar
  14. 14.
    Hamdan AL, Jaffal H, Btaiche R, et al. Laryngopharyngeal symptoms in patients with asthma: a cross-sectional controlled study. Clin Respir J. 2016;10(1):40–7. Scholar
  15. 15.
    Brigham EP, West NE. Diagnosis of asthma: diagnostic testing. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S27–30. Scholar
  16. 16.
    Andrici J, Cox MR, Eslick GD. Cigarette smoking and the risk of Barrett’s esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2013;28(8):1258–73. Scholar
  17. 17.
    Cook MB, Shaheen NJ, Anderson LA, et al. Cigarette smoking increases risk of Barrett’s esophagus: an analysis of the Barrett’s and Esophageal adenocarcinoma consortium. Gastroenterology. 2012;142(4):744–53. Scholar
  18. 18.
    Tramacere I, La Vecchia C, Negri E. Tobacco smoking and esophageal and gastric cardia adenocarcinoma. Epidemiology. 2011;22(3):344–9. Scholar
  19. 19.
    Dicpinigaitis PV. Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):169S–73S. Scholar
  20. 20.
    Chan NJ, Soliman AMS. Angiotensin converting enzyme inhibitor-related angioedema. Ann Otol Rhinol Laryngol. 2015;124(2):89–96. Scholar
  21. 21.
    Haft S, Carey RM, Farquhar D, Mirza N. Anticholinergic medication use is associated with globus pharyngeus. J Laryngol Otol. 2016;130(12):1125–9. Scholar
  22. 22.
    Kraichely RE, Arora AS, Murray JA. Opiate-induced oesophageal dysmotility. Aliment Pharmacol Ther. 2010;31(5):601–6. Scholar
  23. 23.
    Tuteja AK, Biskupiak J, Stoddard GJ, Lipman AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol Motil. 2010;22(4):424–30, e96. Scholar
  24. 24.
    Traister RS, Fajt ML, Petrov AA. The morbidity and cost of vocal cord dysfunction misdiagnosed as asthma. Allergy Asthma Proc. 2016;37(2):25–31. Scholar
  25. 25.
    Traister RS, Fajt ML, Landsittel D, Petrov AA. A novel scoring system to distinguish vocal cord dysfunction from asthma. J Allergy Clin Immunol Pract. 2014;2(1):65–9. Scholar
  26. 26.
    Patel AK, Mildenhall NR, Kim W, Carroll TL. Symptom overlap between laryngopharyngeal reflux and glottic insufficiency in vocal fold atrophy patients. Ann Otol Rhinol Laryngol. 2014;123(4):265–70. Scholar
  27. 27.
    Ford CN. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294(12):1534. Scholar
  28. 28.
    Gooi Z, Ishman SL, Bock JM, Blumin JH, Akst LM. Changing patterns in reflux care: 10-year comparison of ABEA members. Ann Otol Rhinol Laryngol. 2015;124(12):940–6. Scholar
  29. 29.
    Chang AB, Lasserson TJ, Kiljander TO, Connor FL, Gaffney JT, Garske LA. Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux. BMJ. 2006;332(7532):11–7. Scholar
  30. 30.
    Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101(11):2646–54. Scholar
  31. 31.
    Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116(2):254–60. Scholar
  32. 32.
    Carroll TL, Werner A, Nahikian K, Dezube A, Roth DF. Rethinking the laryngopharyngeal reflux treatment algorithm: evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease. Laryngoscope. 2017;127:S1–13. Scholar
  33. 33.
    Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol. 2012;107(7):1011–9. Scholar
  34. 34.
    McDonald EG, Milligan J, Frenette C, Lee TC. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med. 2015;175(5):784–91. Scholar
  35. 35.
    Klepser DG, Collier DS, Cochran GL. Proton pump inhibitors and acute kidney injury: a nested case-control study. BMC Nephrol. 2013;14:150. Scholar
  36. 36.
    Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia. JAMA Neurol. 2016; Scholar
  37. 37.
    Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16(2):274–7. Accessed 21 July 2016CrossRefGoogle Scholar
  38. 38.
    Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope. 2004;114(9):1549–56. Scholar
  39. 39.
    Brauer DL, Tse KY, Lin JC, Schatz MX, Simon RA. The utility of the reflux symptom index for diagnosis of laryngopharyngeal reflux in an allergy patient population. J Allergy Clin Immunol Pract. 2017; Scholar
  40. 40.
    Belafsky PC, Postma GN, Koufman JA. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111(8):1313–7. Scholar
  41. 41.
    Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002;16(4):564–79. Accessed 21 July 2016.CrossRefGoogle Scholar
  42. 42.
    Milstein CF, Charbel S, Hicks DM, Abelson TI, Richter JE, Vaezi MF. Prevalence of laryngeal irritation signs associated with reflux in asymptomatic volunteers: impact of endoscopic technique (rigid vs. flexible laryngoscope). Laryngoscope. 2005;115(12):2256–61. Scholar
  43. 43.
    Chang BA, MacNeil SD, Morrison MD, Lee PK. The reliability of the reflux finding score among general otolaryngologists. J Voice. 2015;29(5):572–7. Scholar
  44. 44.
    Lee YC, Kwon OE, Park JM, Eun YG. Do laryngoscopic findings reflect the characteristics of reflux in patients with laryngopharyngeal reflux? Clin Otolaryngol. 2017; Scholar
  45. 45.
    Rosen R, Mitchell PD, Amirault J, Amin M, Watters K, Rahbar R. The edematous and erythematous airway does not denote pathologic gastroesophageal reflux. J Pediatr. 2017;183:127–31. Scholar
  46. 46.
    Streckfuss A, Bosch N, Plinkert PK, Baumann I. Transnasal flexible esophagoscopy (TNE): an evaluation of the patient’s experience and time management. Eur Arch Otorhinolaryngol. 2014;271(2):323–8. Scholar
  47. 47.
    Howell RJ, Pate MB, Ishman SL, et al. Prospective multi-institutional transnasal esophagoscopy: predictors of a change in management. Laryngoscope. 2016;126(12):2667–71. Scholar
  48. 48.
    Peery AF, Hoppo T, Garman KS, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75(5):945–53.e2. Scholar
  49. 49.
    Madanick RD. Extraesophageal presentations of GERD. Gastroenterol Clin North Am. 2014;43(1):105–20. Scholar
  50. 50.
    Kaufman JA, Houghland JE, Quiroga E, Cahill M, Pellegrini CA, Oelschlager BK. Long-term outcomes of laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD)-related airway disorder. Surg Endosc. 2006;20(12):1824–30. Scholar
  51. 51.
    Wo JM, Koopman J, Harrell SP, Parker K, Winstead W, Lentsch E. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol. 2006;101(9):1972–8; quiz 2169. Scholar
  52. 52.
    Cool M, Poelmans J, Feenstra L, Tack J. Characteristics and clinical relevance of proximal esophageal pH monitoring. Am J Gastroenterol. 2004;99(12):2317–23. Scholar
  53. 53.
    Ayazi S, Lipham JC, Hagen JA, et al. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J Gastrointest Surg. 2009;13(8):1422–9. Scholar
  54. 54.
    Yadlapati R, Adkins C, Jaiyeola D-M, et al. Abilities of oropharyngeal pH tests and salivary pepsin analysis to discriminate between asymptomatic volunteers and subjects with symptoms of laryngeal irritation. Clin Gastroenterol Hepatol. 2016;14(4):535–42.e2. Scholar
  55. 55.
    Yadlapati R, Pandolfino JE, Lidder AK, et al. Oropharyngeal pH testing does not predict response to proton pump inhibitor therapy in patients with laryngeal symptoms. Am J Gastroenterol. 2016;111(11):1517–24. Scholar
  56. 56.
    Sifrim D, Dupont L, Blondeau K, Zhang X, Tack J, Janssens J. Weakly acidic reflux in patients with chronic unexplained cough during 24 hour pressure, pH, and impedance monitoring. Gut. 2005;54(4):449–54. Scholar
  57. 57.
    Blondeau K, Dupont LJ, Mertens V, Tack J, Sifrim D. Improved diagnosis of gastro-oesophageal reflux in patients with unexplained chronic cough. Aliment Pharmacol Ther. 2007;25(6):723–32. Scholar
  58. 58.
    Kim SI, Kwon OE, Na SY, Lee YC, Park JM, Eun YG. Association between 24-hour combined multichannel intraluminal impedance-pH monitoring and symptoms or quality of life in patients with laryngopharyngeal reflux. Clin Otolaryngol. 2017;42(3):584–91. Scholar
  59. 59.
    Hoppo T, Sanz AF, Nason KS, et al. How much pharyngeal exposure is “Normal”? normative data for laryngopharyngeal reflux events using hypopharyngeal multichannel intraluminal impedance (HMII). J Gastrointest Surg. 2012;16(1):16–25. Scholar
  60. 60.
    Zerbib F, Roman S, Bruley Des Varannes S, et al. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clin Gastroenterol Hepatol. 2013;11(4):366–72. Scholar
  61. 61.
    Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol. 2004;99(6):1037–43. Scholar
  62. 62.
    Hoppo T, Komatsu Y, Jobe BA. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance. Dis Esophagus. 2014;27(6):530–7. Scholar
  63. 63.
    Komatsu Y, Hoppo T, Jobe BA. Proximal reflux as a cause of adult-onset asthma. JAMA Surg. 2013;148(1):50. Scholar
  64. 64.
    Hoppo T, Komatsu Y, Jobe BA. Antireflux surgery in patients with chronic cough and abnormal proximal exposure as measured by hypopharyngeal multichannel intraluminal impedance. JAMA Surg. 2013;148(7):608. Scholar
  65. 65.
    Dulery C, Lechot A, Roman S, et al. A study with pharyngeal and esophageal 24-hour pH-impedance monitoring in patients with laryngopharyngeal symptoms refractory to proton pump inhibitors. Neurogastroenterol Motil. 2017;29(1):e12909. Scholar
  66. 66.
    Hayat JO, Gabieta-Somnez S, Yazaki E, et al. Pepsin in saliva for the diagnosis of gastro-oesophageal reflux disease. Gut. 2015;64(3):373–80. Scholar
  67. 67.
    Calvo-Henríquez C, Ruano-Ravina A, Vaamonde P, Martínez-Capoccioni G, Martín-Martín C. Is pepsin a reliable marker of laryngopharyngeal reflux? A systematic review. Otolaryngol Head Neck Surg. 2017;157(3):385–91. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of GastroenterologyBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Division of OtolaryngologyBrigham and Women’s HospitalBostonUSA

Personalised recommendations